Literature DB >> 30094536

Melanoma treatment: from conventional to nanotechnology.

Harshita Mishra1, Pawan K Mishra2, Adam Ekielski3, Manu Jaggi4, Zeenat Iqbal1, Sushama Talegaonkar5,6.   

Abstract

INTRODUCTION: Melanoma is the most serious form of skin cancer causing most of the skin cancer-related deaths. The incidence of melanoma has risen so dramatically over past few years that no other solid or blood malignancy comes close to it in terms of increased incidence. The main problem associated with the treatment of melanoma is low response rate to the existing treatment modalities, which in turn is due to the incomplete response by chemotherapeutic agents and inherent resistance of melanoma cells.
MATERIALS AND METHODS: Conventional therapeutic strategies, as well as, recent literature on melanoma have been thoroughly studied. This review summarizes the base of anti-melanoma treatment with conventional chemotherapeutic drugs, followed by an account of recent studies which explored the potential of nanotechnology and newer strategies and agents in melanoma treatment.
CONCLUSION: Although melanoma is curable if detected in its early localized form, metastatic melanoma continues to be a therapeutic challenge. Metastatic melanoma has a very poor prognosis and conventional therapies have not improved the outcomes of the treatment so far. For this reason, newer combinations of anti-melanoma drugs and newer strategies utilizing nanotechnology have been constantly explored.

Entities:  

Keywords:  Anti-melanoma; Dacarbazine; Immuno-therapy; Melanoma treatment; Nano-agents; Nanotechnology; Targeted therapy

Mesh:

Substances:

Year:  2018        PMID: 30094536     DOI: 10.1007/s00432-018-2726-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  138 in total

1.  Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.

Authors:  Iara F Kretzer; Durvanei A Maria; Raul C Maranhão
Journal:  Cell Oncol (Dordr)       Date:  2012-10-03       Impact factor: 6.730

2.  Carboxylated phytosterol derivative-introduced liposomes for skin environment-responsive transdermal drug delivery system.

Authors:  Naoko Yamazaki; Satoshi Yamakawa; Takumi Sugimoto; Yuta Yoshizaki; Ryoma Teranishi; Takaaki Hayashi; Aki Kotaka; Chiharu Shinde; Takayuki Kumei; Yasushi Sumida; Toru Shimizu; Yukihiro Ohashi; Eiji Yuba; Atsushi Harada; Kenji Kono
Journal:  J Liposome Res       Date:  2017-09-05       Impact factor: 3.648

3.  Enhancement of radiosensitivity of melanoma cells by pegylated gold nanoparticles under irradiation of megavoltage electrons.

Authors:  Mehdi Mousavi; Hassan Ali Nedaei; Samideh Khoei; Samira Eynali; Karim Khoshgard; Mostafa Robatjazi; Rasoul Iraji Rad
Journal:  Int J Radiat Biol       Date:  2016-10-05       Impact factor: 2.694

4.  Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

Authors:  L Serrone; M Zeuli; F M Sega; F Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2000-03

5.  Long term response to chemotherapy in patients with visceral metastatic melanoma.

Authors:  A S Coates; E Segelov
Journal:  Ann Oncol       Date:  1994-03       Impact factor: 32.976

6.  Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Authors:  Antoni Ribas; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Adil Daud; Lawrence Flaherty; Theodore Logan; Bartosz Chmielowski; Karl Lewis; Damien Kee; Peter Boasberg; Ming Yin; Iris Chan; Luna Musib; Nicholas Choong; Igor Puzanov; Grant A McArthur
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

7.  Nanoformulations of a potent copper-based aquaporin inhibitor with cytotoxic effect against cancer cells.

Authors:  Mariana Nave; Rui E Castro; Cecília Mp Rodrigues; Angela Casini; Graça Soveral; Maria Manuela Gaspar
Journal:  Nanomedicine (Lond)       Date:  2016-07-07       Impact factor: 5.307

Review 8.  Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches.

Authors:  Zoe Apalla; Dorothée Nashan; Richard B Weller; Xavier Castellsagué
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-01

9.  Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes.

Authors:  Zhongjian Chen; Tianpeng Zhang; Baojian Wu; Xingwang Zhang
Journal:  Int J Nanomedicine       Date:  2016-03-11

10.  Synergistic locoregional chemoradiotherapy using a composite liposome-in-gel system as an injectable drug depot.

Authors:  Shruti GuhaSarkar; Kamal Pathak; Niyati Sudhalkar; Prachi More; Jayant Sastri Goda; Vikram Gota; Rinti Banerjee
Journal:  Int J Nanomedicine       Date:  2016-12-01
View more
  26 in total

Review 1.  Selumetinib: a selective MEK1 inhibitor for solid tumor treatment.

Authors:  Mohaddeseh Hedayat; Reza Jafari; Naime Majidi Zolbanin
Journal:  Clin Exp Med       Date:  2022-02-16       Impact factor: 3.984

Review 2.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

3.  M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors.

Authors:  C Barceló; P Sisó; I de la Rosa; C Megino-Luque; R Navaridas; O Maiques; I Urdanibia; N Eritja; X Soria; M Potrony; N Calbet-Llopart; S Puig; X Matías-Guiu; R M Martí; A Macià
Journal:  Br J Cancer       Date:  2022-06-20       Impact factor: 9.075

4.  ADT-OH inhibits malignant melanoma metastasis in mice via suppressing CSE/CBS and FAK/Paxillin signaling pathway.

Authors:  Fang-Fang Cai; Huang-Ru Xu; Shi-Hui Yu; Ping Li; Yan-Yan Lu; Jia Chen; Zhi-Qian Bi; Hui-Song Sun; Jian Cheng; Hong-Qin Zhuang; Zi-Chun Hua
Journal:  Acta Pharmacol Sin       Date:  2021-11-18       Impact factor: 7.169

5.  Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation.

Authors:  Yiling Zhang; Ningning Cui; Gang Zheng
Journal:  Oncol Lett       Date:  2020-01-08       Impact factor: 2.967

6.  LncRNA MIAT promotes the proliferation, migration, and invasion of melanoma cells through recruiting TCF12 and activating NFAT5.

Authors:  Fei Lu; Ying Song; Shuo Cui; Huafei Zhao; Yuhua Chen; Hao Du
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 7.  Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy.

Authors:  Hongzhen Bai; Jianwei Wang; Zhongbao Li; Guping Tang
Journal:  Int J Mol Sci       Date:  2019-04-28       Impact factor: 5.923

8.  Identification and Validation of Immune-Related lncRNA Signature as a Prognostic Model for Skin Cutaneous Melanoma.

Authors:  Shuai Ping; Siyuan Wang; Jinbing He; Jianghai Chen
Journal:  Pharmgenomics Pers Med       Date:  2021-06-03

9.  NCK1-AS1 promotes the progression of melanoma by accelerating cell proliferation and migration via targeting miR-526b-5p/ADAM15 axis.

Authors:  Quan Lin; Yan Jia; Duo Zhang; Hongjuan Jin
Journal:  Cancer Cell Int       Date:  2021-07-12       Impact factor: 5.722

Review 10.  Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid.

Authors:  Claudia Ceci; Pedro M Lacal; Lucio Tentori; Maria Gabriella De Martino; Roberto Miano; Grazia Graziani
Journal:  Nutrients       Date:  2018-11-14       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.